Search Results for: Cannabis

Assessing Abuse Potential of Cannabinoids: Lessons Learned from Past CNS-Active Drug Development

The confusing and conflicting legal status of cannabis and its active constituents can inhibit product development as companies encounter significant and unique barriers to approval and appropriate scheduling. In a complementary webinar, Jack Henningfield, Ph.D., and Daniel Wang described how the development and regulatory submission of other CNS-active drugs, including the development of the FDA-required abuse potential assessment, provide important precedents and models for cannabinoids.... Read More >

Medicinal Cannabis: Lessons for Scheduling and FDA’s Expectations for Respiratory Drug Delivery

Development of cannabinoid-based medicines is a rapidly growing area of interest for patients with unmet needs as well as the pharmaceutical industry. The path forward, however, is fraught with technical and regulatory issues that require a thoughtful approach early and throughout the development process. At two recent medicinal cannabinoid conferences, CannMed 2017 and the 2017... Read more »... Read More >